| diastolic dysfunction |
150 |
| echocardiography |
150 |
| fibromyalgia syndrome |
150 |
| isovolumetric relaxation time |
150 |
| mitral e-wave deceleration time |
150 |
| freund’s complete adjuvant-induced arthritis |
137 |
| ozone |
137 |
| oxidative stress |
137, 198 |
| rheumatoid arthritis |
137, 160, 143, 128, 154, 174, 213, 198 |
| outcome measures |
160 |
| sleep disorders |
160 |
| disease activity |
143 |
| european league against rheumatism |
143 |
| female |
143 |
| passive smoking |
143 |
| response |
143 |
| epidemiology |
128 |
| prevalence |
128 |
| spondyloarthritis |
128 |
| anti-ro/sjögren’s syndrome type a antibodies |
225 |
| complete atrioventricular block |
225 |
| sjögren’s syndrome |
225 |
| non-tumor necrosis factor biologics |
154 |
| tofacitinib |
154 |
| behçet’s disease |
221 |
| neuro-behçet |
221 |
| ptosis |
221 |
| disease activity score 28 |
174 |
| fibromyalgia |
174 |
| short form survey-36 |
174 |
| carbohydrate antigen 19-9 |
190 |
| carcinoembryonic antigen |
190 |
| connective tissue diseases |
190 |
| interstitial lung diseases |
190 |
| prognosis |
190 |
| endothelial damage |
168 |
| juvenile idiopathic arthritis |
168 |
| serum endocan |
168 |
| caregiver reaction assessment |
213 |
| caregiver strain index |
213 |
| disease activity score-28 |
213 |
| osteoarthritis |
213 |
| localized scleroderma |
230 |
| magnetic resonance imaging |
230 |
| methotrexate |
230 |
| mycophenolate mofetil |
230 |
| osteomyelitis |
230 |
| bee venom |
198 |
| hesperidin |
198 |
| inflammation |
198 |
| interferon-induced helicase c domain-containing protein 1 gene |
181 |
| vascular |
181 |
| von willebrand factor |
181 |
| expert opinions |
108 |
| management |
108 |
| psoriatic arthritis |
108 |
| treatment recommendation |
108 |
| turkish league against rheumatism |
108 |
